Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection, New England Journal of Medicine, vol.361, issue.6, pp.580-593, 2009. ,
DOI : 10.1056/NEJMoa0808010
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection, New England Journal of Medicine, vol.364, issue.25, pp.2405-2416, 2011. ,
DOI : 10.1056/NEJMoa1012912
Boceprevir for Untreated Chronic HCV Genotype 1 Infection, New England Journal of Medicine, vol.364, issue.13, pp.1195-1206, 2011. ,
DOI : 10.1056/NEJMoa1010494
URL : https://hal.archives-ouvertes.fr/hal-00867494
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C, New England Journal of Medicine, vol.368, issue.1, pp.34-44, 2013. ,
DOI : 10.1056/NEJMoa1208953
ABT-450/r???Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis, New England Journal of Medicine, vol.370, issue.21, pp.1973-1982, 2014. ,
DOI : 10.1056/NEJMoa1402869
URL : http://diposit.ub.edu/dspace/bitstream/2445/118403/1/661907.pdf
Eligibility and Safety of Triple Therapy for Hepatitis C: Lessons Learned from the First Experience in a Real World Setting, PLoS ONE, vol.143, issue.2, p.23383319, 2013. ,
DOI : 10.1371/journal.pone.0055285.t004
Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection, Gastroenterology, vol.141, issue.6, pp.2047-2055, 2011. ,
DOI : 10.1053/j.gastro.2011.08.051
HCV direct-acting antiviral agents: the best interferon-free combinations, Liver International, vol.15, issue.Suppl, pp.69-78, 2014. ,
DOI : 10.1517/14656566.2014.857656
URL : http://onlinelibrary.wiley.com/doi/10.1111/liv.12423/pdf
Recommendations for testing, managing, and treating hepatitis C. Available: http://www.hcvguidelines.org. Accessed 21, 2015. ,
Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry, Journal of Hepatology, vol.62, issue.5, pp.1040-1046, 2015. ,
DOI : 10.1016/j.jhep.2014.10.044
ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C, Nature, vol.18, issue.7287, pp.405-408, 2010. ,
DOI : 10.1001/jama.1957.72980250010016
Variants in the ITPA Gene Protect Against Ribavirin-Induced Hemolytic Anemia and Decrease the Need for Ribavirin Dose Reduction, Gastroenterology, vol.139, issue.4, pp.1181-1189, 2010. ,
DOI : 10.1053/j.gastro.2010.06.016
ITPA Polymorphism Affects Ribavirin-Induced Anemia and Outcomes of Therapy???A Genome-Wide Study of Japanese HCV Virus Patients, Gastroenterology, vol.139, issue.4, pp.1190-1197, 2010. ,
DOI : 10.1053/j.gastro.2010.06.071
Inosine Triphosphate Protects Against Ribavirin-Induced Adenosine Triphosphate Loss by Adenylosuccinate Synthase Function, Gastroenterology, vol.140, issue.4, pp.1314-1321, 2011. ,
DOI : 10.1053/j.gastro.2010.12.038
Unraveling the genetic predisposition of ribavirin-induced anaemia, Journal of Hepatology, vol.53, issue.5, pp.971-973, 2010. ,
DOI : 10.1016/j.jhep.2010.06.007
Faldaprevir and Deleobuvir for HCV Genotype 1 Infection, New England Journal of Medicine, vol.369, issue.7, pp.630-639, 2013. ,
DOI : 10.1056/NEJMoa1213557
Treatment of HCV with ABT-450/r???Ombitasvir and Dasabuvir with Ribavirin, New England Journal of Medicine, vol.370, issue.17, pp.1594-1603, 2014. ,
DOI : 10.1056/NEJMoa1315722
ABT-450/r???Ombitasvir and Dasabuvir with or without Ribavirin for HCV, New England Journal of Medicine, vol.370, issue.21, pp.1983-1992, 2014. ,
DOI : 10.1056/NEJMoa1402338
Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial, The Lancet, vol.385, issue.9986, pp.2502-2509, 2015. ,
DOI : 10.1016/S0140-6736(15)60159-3
Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial, Hepatology, vol.361, issue.3, pp.974-984, 2013. ,
DOI : 10.1056/NEJMoa0808010
STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection, Journal of Hepatology, vol.62, issue.6, 2015. ,
DOI : 10.1016/j.jhep.2014.12.024
genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response, Hepatology, vol.364, issue.1, pp.2152-2160, 2014. ,
DOI : 10.1056/NEJMoa1012912
URL : http://onlinelibrary.wiley.com/doi/10.1002/hep.27022/pdf
IL28B But Not ITPA Polymorphism Is Predictive of Response to Pegylated Interferon, Ribavirin, and Telaprevir Triple Therapy in Patients With Genotype 1 Hepatitis C, The Journal of Infectious Diseases, vol.204, issue.1, pp.84-93, 2011. ,
DOI : 10.1093/infdis/jir210
Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy, Journal of Hepatology, vol.59, issue.4, pp.667-674, 2013. ,
DOI : 10.1016/j.jhep.2013.05.017
Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus, Gastroenterology, vol.139, issue.1, pp.120-129, 2010. ,
DOI : 10.1053/j.gastro.2010.04.013
Genomics and HCV infection: Progression of fibrosis and treatment response, Journal of Hepatology, vol.57, issue.5, pp.1110-1125, 2012. ,
DOI : 10.1016/j.jhep.2012.05.016
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection, New England Journal of Medicine, vol.370, issue.20, pp.1889-1898, 2014. ,
DOI : 10.1056/NEJMoa1402454
URL : http://diposit.ub.edu/dspace/bitstream/2445/118704/1/661902.pdf